XenaCare Holdings (OTCBB: XCHO) has Announced That the Chain Drug Marketing Association (CDMA) Will Begin Taking Inventory of Cobroxin for Redistribution and Sale Through its 6,000 Member Pharmacies
DELRAY BEACH, Fla., Nov 04, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States. "As one of the largest pharmacy organizations in the United States, we are excited to be working with the CDMA to distribute Cobroxin to its independent pharmacy members," explained Frank Rizzo, President of XenaCare Holdings. "Having a presence in CDMA member pharmacies will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign," he concluded.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- More Potent than Morphine
-- Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About Nutra Pharma:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment